Solutions for clinical-grade manufacturing of gene-engineered NK cells
Sponsor
Due to their central role in tumor immunosurveillance and unique ability to recognize target cells in a non-MHC-restricted manner, natural killer (NK) cells represent a promising immunotherapy for cancer treatment, in particular as an off-the-shelf approach.
Inspired by the success of CAR T cell therapies, researchers are incorporating the genetic engineering of NK cells as a strategy in the latest pre-clinical and clinical studies to empower NK cells and enhance their anti-tumor effector functions.
As clinical trials progress, there is an increased need to establish standardized manufacturing methods for gene-engineered NK cells for cancer therapy.
However, it is challenging to genetically modify and ex vivo-expand NK cells — and these two steps are crucial for the sufficient generation of functional engineered NK cells.
In this webinar, Miltenyi's Maria Delso Vallejo, PhD will address how to efficiently manufacture gene-engineered NK cells for clinical applications using an automated and closed system.
Furthermore, Maria will explore options to upscale NK cell manufacturing and standardize the in-process control (IPC) and quality control (QC) steps associated with the process.
- Discover solutions to standardize the clinical manufacturing of your gene-engineered NK cells using an automated and closed system
- Learn how you can achieve robust ex vivo expansion of your NK cells and explore options for upscaling
- Understand how to leverage automated flow cytometric analysis for your IPC/QC
SPEAKERS
You might also like
Clinical-scale non-viral gene edited CAR-NK cells for cell therapy
Developing off-the-shelf CAR-NK cells targeting CD70: updates from preclinical and early clinical studies
CAR-NK production for clinical applications using BaEV lentivirus and the NK cell engineering platform
Enabling allogeneic cell therapy development: scaling up generation of PSC-derived NK cells
